Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis

Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis

Background and Objective: Myasthenia gravis (MG) is an autoimmune neuromuscular disease. Nearly 10–30% of patients with MG are refractory to conventional therapy. Rituximab (RTX), a monoclonal antibody targeting CD20, is increasingly used in autoimmune disorders. We performed a systematic review and...

Full description

Bibliographic Details
Main Authors: Cong Zhao, Meng Pu, Dawei Chen, Jin Shi, Zhuyi Li, Jun Guo, Guangyun Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Neurology
Subjects:
myasthenia gravis
refractory
rituximab
effectiveness
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.736190/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.736190/full

Similar Items